HOME INFUSION THERAPY SERVICE BUSINESS PLAN
Â
I. Executive Summary
Company Description
The company is a U.S.-based mobile healthcare provider launching in 2026 that delivers professional home-based intravenous (IV) treatments. We operate in the home health and infusion therapy sector and provide clinical-level care via a team of highly skilled Registered Nurses, including oncology and pediatric specialists. Our core services are supervised IV infusions, medication administration, and post-infusion monitoring delivered in patients’ homes, supported by an integrated EHR and scheduling platform that coordinates care with the broader healthcare system. One clear strength: clinical expertise brought to the home with technology that ensures safety, privacy, and continuity of care.
We target older adults and medically complex patients who prefer home-based care and health systems seeking outpatient alternatives to hospital infusions. Short-term goals: commence operations in 2026, secure payer agreements, and complete pilot markets with validated clinical protocols. Long-term goals: rapid scale across multiple U.S. regions, embed with referring health systems, and achieve sustainable unit economics through volume, standardized clinical pathways, and tech-enabled scheduling. One-liner: delivering hospital-grade IV care at home, safely and at scale.
Â
Problem
Patients needing intravenous treatments face significant logistical, financial, and clinical risks: frequent travel to hospitals, high visit costs, and increased exposure to healthcare-acquired infections for immunocompromised individuals.
These burdens reduce adherence, worsen outcomes, and place measurable time and financial strain on families and caregivers who manage recurring transportation and scheduling.
There is no widely available, reliable option that combines hospital-level infusion safety with the convenience of home care, leaving a gap between clinical needs and practical patient access.
Â
Solution
Patients who need regular IV therapies face travel burdens, infection risk, high costs, and caregiver strain. Our service sends certified nurses to patient homes to administer antibiotics, biologics, and chemotherapy, coordinates directly with referring physicians, and provides 24/7 on-call clinical support while integrating electronic health records and real-time monitoring to maintain hospital-grade standards and reduce readmissions.
In-home, physician-coordinated IV care that preserves hospital standards.
Â
Mission Statement
Our mission is to transform patient care by delivering the highest standard of clinical infusion therapy in the comfort and safety of the home. We improve outcomes through personalized nursing, advanced technology, and seamless coordination with physicians and payors, reducing the burden of chronic and acute illness on patients and families. We commit to clinical excellence, compassionate service, and value-based care to be the preferred partner for patients, clinicians, and payors.
Â
Key Success Factors
Critical operational and market capabilities that will determine our ability to scale and sustain profitability.
-
Recruit and retain 29 specialized nurses in 2026 to deliver licensed home infusion care.
-
Establish referral partnerships with major hospitals and specialty clinics to drive steady patient volume.
-
Maintain HIPAA-compliant integrated platform for efficient billing and clinical documentation.
-
Achieve 85% specialist utilization to secure operational profitability and capacity efficiency.
-
Obtain in-network status with major payors to ensure patient access and protect the 86.33% ROE.
Financial Summary
Brief: First-year revenue of $5,467,000 with rapid growth to $17,728,000 by 2028 and strong profitability throughout.
Â
Ratio |
2026 |
2027 |
2028 |
Projected Revenue |
$5,467,000 |
$9,913,000 |
$17,728,000 |
Projected EBITDA |
$3,768,000 |
$7,245,000 |
$13,450,000 |
Expected ROI |
86.33% (ROE) |
— |
— |
Â
Financial requirements: Minimum cash required $905,000 (minimum cash month Jan-26). Breakeven Jan-26; months to payback 1. Reported IRR 0% and ROE 86.33%.
Outlook: The business reaches positive cashflow immediately and scales to EBITDA of $13.45M in 2028 and $34.129M by 2030.
Â
Funding Requirements
The business requires $905,000 in initial funding to cover CAPEX, staffing, rent, marketing, and working capital, supporting a launch that projects $5,467,000 revenue and $3,768,000 EBITDA in 2026, achieves breakeven and payback in month one, and scales to $43,016,000 revenue by year five.
Â
Categories |
Amount, USD |
Product Development |
$0 |
Marketing (annual) |
$42,000 |
Operations (first-month rent) |
$6,500 |
Staffing (Clinical Director) |
$145,000 |
CAPEX (initial) |
$250,000 |
Licenses, insurance, technology platforms |
$0 |
Working capital |
$461,500 |
Total funding required |
$905,000 |
Â